Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

Comparison of dual versus triple antiplatelet therapy after drug-eluting stent according to stent length (from the pooled analysis of DECLARE trials).

Lee SW, Lee JY, Ahn JM, Park DW, Han S, Park YK, Lee WS, Jang JY, Kwon CH, Park GM, Cho YR, Kim WJ, Kang SJ, Kim YH, Lee CW, Kim JJ, Park SW, Park SJ.

Am J Cardiol. 2013 Dec 1;112(11):1738-44. doi: 10.1016/j.amjcard.2013.08.008.

PMID:
24063835
2.

A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial.

Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Kang SJ, Park SJ, Lee JH, Choi SW, Seong IW, Lee NH, Cho YH, Shin WY, Lee SJ, Lee SW, Hyon MS, Bang DW, Choi YJ, Kim HS, Lee BK, Lee K, Park HK, Park CB, Lee SG, Kim MK, Park KH, Park WJ; DECLARE-LONG II Study Investigators..

J Am Coll Cardiol. 2011 Mar 15;57(11):1264-70. doi: 10.1016/j.jacc.2010.10.035.

3.

Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).

Lee SW, Chun KJ, Park SW, Kim HS, Kim YH, Yun SC, Kim WJ, Lee JY, Park DW, Lee CW, Hong MK, Rhee KS, Chae JK, Ko JK, Park JH, Lee JH, Choi SW, Jeong JO, Seong IW, Jon S, Cho YH, Lee NH, Kim JH, Park SJ.

Am J Cardiol. 2010 Jan 15;105(2):168-73. doi: 10.1016/j.amjcard.2009.08.667.

PMID:
20102913
4.

Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients).

Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ.

J Am Coll Cardiol. 2008 Mar 25;51(12):1181-7. doi: 10.1016/j.jacc.2007.11.049.

5.

Differential impact of cilostazol on restenosis according to implanted stent type (from a pooled analysis of three DECLARE randomized trials).

Lee SW, Ahn JM, Han S, Park GM, Cho YR, Lee WS, Jang JY, Kwon CH, Lee JY, Kim WJ, Kang SJ, Kim YH, Lee CW, Kim JJ, Park SW, Park SJ.

Am J Cardiol. 2013 Nov 1;112(9):1328-34. doi: 10.1016/j.amjcard.2013.06.010.

PMID:
23890573
6.

Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial.

Ahn Y, Jeong MH, Jeong JW, Kim KH, Ahn TH, Kang WC, Park CG, Kim JH, Chae IH, Nam CW, Hur SH, Bae JH, Kim KY, Oh SK.

Circ J. 2008 Jan;72(1):35-9.

7.

Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).

Lee SW, Park SW, Yun SC, Kim YH, Park DW, Kim WJ, Lee JY, Lee CW, Hong MK, Kim JJ, Park SJ.

Am Heart J. 2010 Feb;159(2):284-291.e1. doi: 10.1016/j.ahj.2009.11.014.

PMID:
20152228
8.

Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial).

Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ; DECLARE-Long Study Investigators..

Am J Cardiol. 2007 Oct 1;100(7):1103-8.

PMID:
17884371
9.
10.

Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation.

Lee BK, Lee SW, Park SW, Lee SW, Park DW, Kim YH, Lee CW, Hong MK, Kim JJ, Jang S, Chi HS, Park SJ.

Am J Cardiol. 2007 Aug 15;100(4):610-4.

PMID:
17697815
11.

Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query.

Singh I, Shafiq N, Pandhi P, Reddy S, Pattanaik S, Sharma Y, Malhotra S.

Br J Clin Pharmacol. 2009 Jul;68(1):4-13. doi: 10.1111/j.1365-2125.2009.03402.x.

12.
13.

[The effects of post coronary stenting triple antiplatelet therapies on platelet functions].

Han YL, Su QF, Li Y, Kang J, Yan CH, Wang SL.

Zhonghua Nei Ke Za Zhi. 2006 Aug;45(8):635-8. Chinese.

PMID:
17074146
14.

Triple antiplatelet therapy with addition of cilostazol to aspirin and clopidogrel for Y-stent-assisted coil embolization of cerebral aneurysms.

Kono K, Shintani A, Yoshimura R, Okada H, Tanaka Y, Fujimoto T, Tomura N, Terada T.

Acta Neurochir (Wien). 2013 Aug;155(8):1549-57. doi: 10.1007/s00701-013-1771-4.

PMID:
23715948
15.

A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation.

Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, Kim DS, Kim DK, Seol SH, Kim DI, Cho KI, Kim BH, Park YH, Je HG, Jeong YH, Kim WJ, Lee JY, Lee SW.

Cardiology. 2012;122(3):133-43. doi: 10.1159/000339238. Review.

PMID:
22832424
17.
18.

Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.

Geng DF, Liu M, Jin DM, Wu W, Deng J, Wang JF.

Cardiology. 2012;122(3):148-57. doi: 10.1159/000338812. Review.

PMID:
22832561
19.

Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation.

Sarafoff N, Ndrepepa G, Mehilli J, Dörrler K, Schulz S, Iijima R, Byrne R, Schömig A, Kastrati A.

J Intern Med. 2008 Nov;264(5):472-80. doi: 10.1111/j.1365-2796.2008.01989.x.

20.

Supplemental Content

Support Center